Abstract
Dementia is a known predictor of mortality, but little is known about disease duration. We therefore aimed to investigate the impact of dementia on survival by estimating years lived with the disease, in total and in different severity stages, and by comparing dementia to other major chronic disorders such as cancer and cardiovascular disease (CVD). During a 7.4-year follow-up of the Kungsholmen project, 371 incident dementia cases of the 1,307 dementia-free persons, aged 75+ at baseline, were clinically diagnosed (DSM-III-R criteria). Diagnoses of cancer and CVD were obtained from the national Stockholm Inpatient Registry System, active since 1969. Disease duration, hazard ratio (HR), and potential years of life lost (PYLL) were derived from Kaplan–Meier survival estimation, the Cox model, and standard life-table analysis, respectively. Dementia was a significant predictor of mortality (HR=1.7; 95% CI: 1.47–1.92) after adjustment for several covariates including comorbidity, accounting for 16% of all deaths. The mean (±SD) survival time after dementia diagnosis was 4.1 (±2.6) years, and more than 2 years were spent in moderate (14-month) and severe (12-month) stages. Women with dementia lived longer than men, as they survived longer in the severe stage (2.1 vs. 0.5 years among 75–84-year-old women compared to coetaneous men). The PYLL were 3.4 for dementia, 3.6 for CVD, and 4.4 for cancer. We found a similar impact of dementia and CVD on survival, but following diagnosis, persons with dementia, and especially women, spent half of their remaining lives in the severe disabling stages of the disease.
Keywords: Cancer, cardiovascular diseases, mortality, dementia, survival, PYLL, Parkinson’s disease.
Current Alzheimer Research
Title:Dementia After Age 75: Survival in Different Severity Stages and Years of Life Lost
Volume: 9 Issue: 7
Author(s): Debora Rizzuto, Rino Bellocco, Miia Kivipelto, Francesca Clerici, Anders Wimo and Laura Fratiglioni
Affiliation:
Keywords: Cancer, cardiovascular diseases, mortality, dementia, survival, PYLL, Parkinson’s disease.
Abstract: Dementia is a known predictor of mortality, but little is known about disease duration. We therefore aimed to investigate the impact of dementia on survival by estimating years lived with the disease, in total and in different severity stages, and by comparing dementia to other major chronic disorders such as cancer and cardiovascular disease (CVD). During a 7.4-year follow-up of the Kungsholmen project, 371 incident dementia cases of the 1,307 dementia-free persons, aged 75+ at baseline, were clinically diagnosed (DSM-III-R criteria). Diagnoses of cancer and CVD were obtained from the national Stockholm Inpatient Registry System, active since 1969. Disease duration, hazard ratio (HR), and potential years of life lost (PYLL) were derived from Kaplan–Meier survival estimation, the Cox model, and standard life-table analysis, respectively. Dementia was a significant predictor of mortality (HR=1.7; 95% CI: 1.47–1.92) after adjustment for several covariates including comorbidity, accounting for 16% of all deaths. The mean (±SD) survival time after dementia diagnosis was 4.1 (±2.6) years, and more than 2 years were spent in moderate (14-month) and severe (12-month) stages. Women with dementia lived longer than men, as they survived longer in the severe stage (2.1 vs. 0.5 years among 75–84-year-old women compared to coetaneous men). The PYLL were 3.4 for dementia, 3.6 for CVD, and 4.4 for cancer. We found a similar impact of dementia and CVD on survival, but following diagnosis, persons with dementia, and especially women, spent half of their remaining lives in the severe disabling stages of the disease.
Export Options
About this article
Cite this article as:
Rizzuto Debora, Bellocco Rino, Kivipelto Miia, Clerici Francesca, Wimo Anders and Fratiglioni Laura, Dementia After Age 75: Survival in Different Severity Stages and Years of Life Lost, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455421
DOI https://dx.doi.org/10.2174/156720512802455421 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Drugs of Abuse and their Detection Methodologies: Contribution of Chemical Sensor
Current Organic Chemistry Combination Therapy of Inhaled Corticosteroids and Long-Acting β2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design <i>Nigella sativa</i> L., Supplementary Plant with Anticholinesterase Effect for Cognition Problems: A Kinetic Study
Current Aging Science Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Disconnection of Language and Memory in Semantic Dementia: A Comparative and Theoretical Analysis
Current Alzheimer Research The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology α-Synuclein Aggregation
Protein & Peptide Letters Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism